Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study

Immune responses after the initial vaccination persisted for the 12 months studied, with little additional response after the booster dose at 6 months

Research

The changing epidemiology of invasive pneumococcal disease

We investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).

Research

Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine

Successful defence against viral pathogens requires the rapid recognition of virus-specific "danger signals" and the activation of both innate and adaptive...

Research

Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcus

Group B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...

Research

Opportunities and challenges of the pulmonary route for vaccination

The respiratory tract is an attractive target for the delivery of vaccine antigens.

Research

Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study

The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.

Research

Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 era

Understanding patterns of bacterial carriage and otitis media (OM) microbiology is crucial for assessing vaccine impact and informing policy. The microbiology of OM can vary with geography, time, and interventions like pneumococcal conjugate vaccines (PCVs). We evaluated the microbiology of nasopharyngeal and middle ear effusions in children living in Western Australia, 11 years following the introduction of PCV13.

News & Events

The Kids Research Institute Australia leads WA arm of Australia’s first needle-free COVID-19 vaccine study

Enrolments for Australia’s first needle-free, gene-based COVID-19 vaccine study – to be led in WA by The Kids Research Institute Australia – are open.

News & Events

Wesfarmers tops 2019 GivingLarge Report

The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.

Research

Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016-2021

Vaccination in pregnancy is the best strategy to reduce complications from influenza or pertussis infection in infants who are too young to be protected directly from vaccination. Pregnant women are also at risk of influenza complications preventable through antenatal vaccination. Both vaccines are funded under the National Immunisation Program for pregnant women in Australia, but coverage is not routinely reported nationally.